DEV

You are viewing our development site. Please share feedback with support@dosevault.ai or on our Discord server. See what is new in the changelog.

Dihexa

Dihexa was reported to bind hepatocyte growth factor (HGF) and potentiate signaling through its receptor c-Met, increasing spinogenesis and synaptogenesis in neuronal models. The principal study supporting this mechanism has been retracted, so the proposed mechanism should be treated as unconfirmed. c-Met is a known oncogene, which is the basis for the theoretical proliferative-risk caution.

Molecular Profile
small-molecule
3 AA Sequence
Evidence grade (Preclinical): Animal or in-vitro studies; no controlled human trials. This grade reflects the overall quality of available research on this compound and does not constitute a clinical recommendation.
CAS
1401708-83-5
Formula
C27H44N4O5
Chain length
3 aa
Sequence
N-hexanoic-Tyr-Ile-(6)aminohexanoic amide (peptidomimetic)
Onset and duration

Cognitive effects may be perceived acutely to within days; sustained benefit depends on continued use.

Storage and reconstitution

Store the lyophilized powder refrigerated (2 to 8 C), or frozen for long-term storage, protected from light. After reconstitution with bacteriostatic water, keep refrigerated and use within about 4 weeks.

Clinical Evidence

What the literature says

Scientific Overview

Evidence is preclinical only; there are no human clinical trials of dihexa. Importantly, the foundational 2014 paper describing its HGF/c-Met mechanism (Benoist CC et al., J Pharmacol Exp Ther) has since been RETRACTED, which further weakens the evidence base. A related prodrug (fosgonimeton) was studied in humans but did not establish efficacy. All use is investigational and educational only; efficacy and safety in humans are unproven.

Last reviewed: 2026-06-15

Research Guide

How users approach this compound

The following reflects patterns observed in research literature and community protocols. This is not medical advice and does not constitute a clinical recommendation.

Research Protocols

Common Dosages

Human dosing

Not established
Not established

No approved or trial-derived human regimen; research and educational context only

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Reported Uses

  • Investigational cognitive enhancement and synaptogenesis (preclinical)
  • Research interest in neurodegenerative disease models (no human benefit shown)

Key Research Benefits

  • Preclinical: increased dendritic spine density and synaptogenesis in hippocampal models
  • Preclinical: reversal of induced learning deficits in rodent tasks
  • Investigational interest in neurodegeneration research (no proven human benefit)

Potential Side Effects

Not established in humans (no clinical trials)
Theoretical oncologic risk from c-Met pathway activation

Considerations and Cautions

  • No human safety data; not for human use outside research
  • Theoretical caution where c-Met-driven proliferation is a concern
  • Avoid in pregnancy or breastfeeding (no data)

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

  • No validated markers: No human trials exist; there are no established compound-specific labs to monitor.

Dose Calculator

Peptide Reconstitution Calculator

mg

Total amount of peptide in the vial.

mL

Volume of water used to mix.

mcg

Draw to this mark

10 Units

or 0.10 mL on a U-100 syringe

Concentration:2.50 mg/mL
Peptide per Unit:25.00 mcg/unit
*Always double-check your calculations. This tool is for educational purposes only.

Dihexa by goal

Read Dihexa's profile filtered through specific research goals.

Related Tools

Not medical advice

Information on DoseVault is for educational purposes only and is not a substitute for medical advice, diagnosis, or treatment from a qualified healthcare provider.